Screener
Amneal Pharmaceuticals, Inc. AMRX Institutional — Net revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 5:19 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001723128-26-000031
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Total Specialty net revenue | 149,295 | 128,043 | 282,560 | 236,340 |
| AvKARE | ||||
| Distribution | 86,930 | 99,663 | 176,079 | 204,558 |
| Government label | 50,207 | 45,418 | 110,156 | 95,558 |
| Institutional | 12,112 | 10,132 | 21,931 | 21,141 |
| Other | 7,740 | 7,827 | 14,840 | 14,198 |
| Total AvKARE net revenue | 156,989 | 163,040 | 323,006 | 335,455 |
| Total net revenue | $796,197 | $724,508 | $1,518,716 | $1,419,928 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Amneal Pharmaceuticals, Inc.'s institutional — net revenue?
- Amneal Pharmaceuticals, Inc. (AMRX) reported institutional — net revenue of $12.11M in Q2 2026.
- How has Amneal Pharmaceuticals, Inc.'s institutional — net revenue changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s institutional — net revenue increased by 19.5% year-over-year, from $10.13M to $12.11M.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s institutional — net revenue?
- Over 4 years (2021 to 2025), Amneal Pharmaceuticals, Inc.'s institutional — net revenue has grown at a 8.9% compound annual growth rate (CAGR), from $25.18M to $35.38M.
- What does institutional — net revenue mean?
- This metric represents the total gross sales generated from the institutional business segment after accounting for returns, allowances, and rebates. It reflects the company's ability to capture market share and monetize its pharmaceutical portfolio through direct sales to hospitals, healthcare systems, and other institutional providers. Monitoring this revenue stream helps investors assess the performance and growth trajectory of the company's B2B healthcare distribution channels.
Ask your AI about Amneal Pharmaceuticals, Inc.'s institutional — net revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude